2
项与 Bivalent Subtype C gp120/MF59(NIAID) 相关的临床试验A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA and of MF59-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
The purpose of this study is to evaluate the safety and immune response to an HIV clade C DNA vaccine and to an MF59-adjuvanted clade C Env protein in healthy, HIV-uninfected adults.
A Phase 1-2 Randomized, Double-blind, Placebo-controlled Clinical Trial of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59® in HIV-uninfected Adults at Low Risk of HIV Infection
The HIV Vaccine Trials Network (HVTN) is doing a study to test a new HIV vaccine combination. HIV is the virus that causes AIDS.
252 people are taking part in this study at multiple sites. The US National Institutes of Health (NIH) is paying for the study.
The investigators are doing this study to answer several questions.
Are the study vaccines safe to give to people?
Are people able to take the study vaccines without becoming too uncomfortable?
How do people's immune systems respond to the study vaccines? (Your immune system protects you from disease.)
100 项与 Bivalent Subtype C gp120/MF59(NIAID) 相关的临床结果
100 项与 Bivalent Subtype C gp120/MF59(NIAID) 相关的转化医学
100 项与 Bivalent Subtype C gp120/MF59(NIAID) 相关的专利(医药)
100 项与 Bivalent Subtype C gp120/MF59(NIAID) 相关的药物交易